Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study

Kayser, Sabine; Reichle, Albrecht; Aulitzky, Walter E.; Orvain, Corentin; Hicheri, Yosr; Spiekermann, Karsten; Arar, Ali; Jost, Edgar; Adès, Lionel; Chermat, Fatiha; Stölzel, Friedrich; Fenaux, Pierre; Thiede, Christian; Krause, Stefan W.; Görner, Martin; Noppeney, Richard; Carre, Martin; Schäfer-Eckart, Kerstin; Wemeau, Mathieu; Rahme, Ramy; Braun, Thorsten; Abraham, Julie; Peterlin, Pierre; Bornhäuser, Martin; Willekens, Christophe; Krämer, Alwin; Bonmati, Caroline; Lebon, Delphine; Aljijakli, Ahmad; Raffoux, Emmanuel; Platzbecker, Uwe; Baldus, Claudia D.; Rigaudeau, Sophie; Lengfelder, Eva; Berthon, Celine; Schlenk, Richard F.; Müller-Tidow, Carsten; Röllig, Christoph; Berceanu, Ana; Götze, Katharina S.; De Wit, Maike; Keller, Ulrich; Niemann, Dirk; Serve, Hubert; Schwänen, Carsten; Haiat, Stephanie; Hiddemann, Wolfgang; Saillard, Colombe; Kunzmann, Volker; Carassou, Philippe; Gnadler, Martina

doi:WOS:000732456400011

Items
Marc 21

001			851907
005			20251103073640.0
024	7	_	\|2 HSB \|a eva483339
024	7	_	\|2 ISSN \|a 0390-6078
024	7	_	\|2 ISSN \|a 1592-8721
024	7	_	\|2 SCOPUS \|a SCOPUS:2-s2.0-85121037273
024	7	_	\|2 WOS \|a WOS:000732456400011
024	7	_	\|2 datacite_doi \|a 10.18154/RWTH-CONV-248995
024	7	_	\|2 doi \|a 10.3324/haematol.2021.278722
024	7	_	\|2 pmid \|a pmid:34047178
037	_	_	\|a RWTH-CONV-248995
041	_	_	\|a English
100	1	_	\|a Kayser, Sabine \|b 0 \|e Corresponding author
245	_	_	\|a Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study \|h online
260	_	_	\|a Pavia \|b Ferrata Storti Found \|c 2021
264	_	1	\|2 Crossref \|3 online \|b Ferrata Storti Foundation (Haematologica) \|c 2021-05-27
336	7	_	\|0 0 \|2 EndNote \|a Journal Article
336	7	_	\|0 PUB:(DE-HGF)16 \|2 PUB:(DE-HGF) \|a Journal Article \|b journal \|m journal
336	7	_	\|2 BibTeX \|a ARTICLE
336	7	_	\|2 DRIVER \|a article
336	7	_	\|2 DataCite \|a Output Types/Journal article
336	7	_	\|2 ORCID \|a JOURNAL_ARTICLE
542	_	_	\|2 Crossref \|i 2021-05-27 \|u https://creativecommons.org/licenses/by-nc/4.0/legalcode
591	_	_	\|a France
591	_	_	\|a Germany
700	1	_	\|a Schlenk, Richard F. \|b 1
700	1	_	\|a Lebon, Delphine \|b 2
700	1	_	\|a Carre, Martin \|b 3
700	1	_	\|a Götze, Katharina S. \|b 4
700	1	_	\|a Stölzel, Friedrich \|b 5
700	1	_	\|a Berceanu, Ana \|b 6
700	1	_	\|a Schäfer-Eckart, Kerstin \|b 7
700	1	_	\|a Peterlin, Pierre \|b 8
700	1	_	\|a Hicheri, Yosr \|b 9
700	1	_	\|a Rahme, Ramy \|b 10
700	1	_	\|a Raffoux, Emmanuel \|b 11
700	1	_	\|a Chermat, Fatiha \|b 12
700	1	_	\|a Krause, Stefan W. \|b 13
700	1	_	\|a Aulitzky, Walter E. \|b 14
700	1	_	\|a Rigaudeau, Sophie \|b 15
700	1	_	\|a Noppeney, Richard \|b 16
700	1	_	\|a Berthon, Celine \|b 17
700	1	_	\|a Görner, Martin \|b 18
700	1	_	\|a Jost, Edgar \|b 19
700	1	_	\|a Carassou, Philippe \|b 20
700	1	_	\|a Keller, Ulrich \|b 21
700	1	_	\|a Orvain, Corentin \|b 22
700	1	_	\|a Braun, Thorsten \|b 23
700	1	_	\|a Saillard, Colombe \|b 24
700	1	_	\|a Arar, Ali \|b 25
700	1	_	\|a Kunzmann, Volker \|b 26
700	1	_	\|a Wemeau, Mathieu \|b 27
700	1	_	\|a De Wit, Maike \|b 28
700	1	_	\|a Niemann, Dirk \|b 29
700	1	_	\|a Bonmati, Caroline \|b 30
700	1	_	\|a Schwänen, Carsten \|b 31
700	1	_	\|a Abraham, Julie \|b 32
700	1	_	\|a Aljijakli, Ahmad \|b 33
700	1	_	\|a Haiat, Stephanie \|b 34
700	1	_	\|a Krämer, Alwin \|b 35
700	1	_	\|a Reichle, Albrecht \|b 36
700	1	_	\|a Gnadler, Martina \|b 37
700	1	_	\|a Willekens, Christophe \|b 38
700	1	_	\|a Spiekermann, Karsten \|b 39
700	1	_	\|a Hiddemann, Wolfgang \|b 40
700	1	_	\|a Müller-Tidow, Carsten \|b 41
700	1	_	\|a Thiede, Christian \|b 42
700	1	_	\|a Röllig, Christoph \|b 43
700	1	_	\|a Serve, Hubert \|b 44
700	1	_	\|a Bornhäuser, Martin \|b 45
700	1	_	\|a Baldus, Claudia D. \|b 46
700	1	_	\|a Lengfelder, Eva \|b 47
700	1	_	\|a Fenaux, Pierre \|b 48
700	1	_	\|a Platzbecker, Uwe \|b 49
700	1	_	\|a Adès, Lionel \|b 50
773	1	8	\|2 Crossref \|3 journal-article \|a 10.3324/haematol.2021.278722 \|b Ferrata Storti Foundation (Haematologica) \|d 2021-05-27 \|n 12 \|p 3100-3106 \|t Haematologica \|v 106 \|x 1592-8721 \|y 2021
773	_	_	\|0 PERI:(DE-600)2805244-4 \|a 10.3324/haematol.2021.278722 \|n 12 \|p 3100-3106 \|t Haematologica \|v 106 \|x 1592-8721 \|y 2021
856	4	_	\|u https://publications.rwth-aachen.de/record/851907/files/851907.pdf \|y OpenAccess
909	C	O	\|o oai:publications.rwth-aachen.de:851907 \|p VDB \|p dnbdelivery \|p driver \|p open_access \|p openaire
914	1	_	\|y 2021
915	1	_	\|0 StatID:(DE-HGF)0031 \|2 StatID \|a Peer reviewed article \|x 0
915	_	_	\|0 LIC:(DE-HGF)CCBYNC4 \|2 HGFVOC \|a Creative Commons Attribution-NonCommercial CC BY-NC 4.0
915	_	_	\|0 StatID:(DE-HGF)0030 \|2 StatID \|a Peer Review \|b DOAJ : Peer review \|d 2020-06-12
915	_	_	\|0 StatID:(DE-HGF)0110 \|2 StatID \|a WoS \|b Science Citation Index \|d 2020-06-12
915	_	_	\|0 StatID:(DE-HGF)0111 \|2 StatID \|a WoS \|b Science Citation Index Expanded \|d 2020-06-12
915	_	_	\|0 StatID:(DE-HGF)0150 \|2 StatID \|a DBCoverage \|b Web of Science Core Collection \|d 2020-06-12
915	_	_	\|0 StatID:(DE-HGF)0160 \|2 StatID \|a DBCoverage \|b Essential Science Indicators \|d 2020-06-12
915	_	_	\|0 StatID:(DE-HGF)0199 \|2 StatID \|a DBCoverage \|b Clarivate Analytics Master Journal List \|d 2020-06-12
915	_	_	\|0 StatID:(DE-HGF)0200 \|2 StatID \|a DBCoverage \|b SCOPUS \|d 2020-06-12
915	_	_	\|0 StatID:(DE-HGF)0300 \|2 StatID \|a DBCoverage \|b Medline \|d 2020-06-12
915	_	_	\|0 StatID:(DE-HGF)0310 \|2 StatID \|a DBCoverage \|b NCBI Molecular Biology Database \|d 2020-06-12
915	_	_	\|0 StatID:(DE-HGF)0320 \|2 StatID \|a DBCoverage \|b PubMed Central \|d 2020-06-12
915	_	_	\|0 StatID:(DE-HGF)0500 \|2 StatID \|a DBCoverage \|b DOAJ \|d 2020-06-12
915	_	_	\|0 StatID:(DE-HGF)0501 \|2 StatID \|a DBCoverage \|b DOAJ Seal \|d 2020-06-12
915	_	_	\|0 StatID:(DE-HGF)0510 \|2 StatID \|a OpenAccess
915	_	_	\|0 StatID:(DE-HGF)0561 \|2 StatID \|a Article Processing Charges \|f 2020-06-12
915	_	_	\|0 StatID:(DE-HGF)0700 \|2 StatID \|a Fees \|d 2020-06-12
915	_	_	\|0 StatID:(DE-HGF)1030 \|2 StatID \|a DBCoverage \|b Current Contents - Life Sciences \|d 2020-06-12
915	_	_	\|0 StatID:(DE-HGF)1050 \|2 StatID \|a DBCoverage \|b BIOSIS Previews \|d 2020-06-12
915	_	_	\|0 StatID:(DE-HGF)1110 \|2 StatID \|a DBCoverage \|b Current Contents - Clinical Medicine \|d 2020-06-12
915	_	_	\|0 StatID:(DE-HGF)1190 \|2 StatID \|a DBCoverage \|b Biological Abstracts \|d 2020-06-12
920	1	_	\|0 I:(DE-82)531040-2_20140620 \|k 531040-2 \|l Klinik und Lehrstuhl für Innere Medizin (mit dem Schwerpunkt Onkologie und Hämatologie) \|x 0
970	_	_	\|a eva483339
980	1	_	\|a FullTexts
980	_	_	\|a I:(DE-82)531040-2_20140620
980	_	_	\|a UNRESTRICTED
980	_	_	\|a VDB
980	_	_	\|a journal
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1002/cncr.11636 \|u Shih LY, Kuo MC, Liang DC. Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia. Cancer. 2003; 98(6):1206-1216.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1002/cncr.27650 \|u Zhang Y, Zhang Z, Li J. Long-term efficacy and safety of arsenic trioxide for firstline treatment of elderly patients with newly diagnosed acute promyelocytic leukemia. Cancer. 2013; 119(1):115-125.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1007/BF02782196 \|u Pantic M, Novak A, Marisavljevic D. Additional chromosome aberrations in acute promyelocytic leukemia: characteristics and prognostic influence. Med Oncol. 2000; 17(4):307-313.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1007/s00277-014-2142-9 \|u Lucena-Araujo AR, Kim HT, Jacomo RH. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline- based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. Ann Hematol. 2014; 93(12):2001-2010.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1007/s00277-016-2622-1 \|u Testa U, Lo-Coco F. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients. Ann Hematol. 2016; 95(5):673-680.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1016/0197-2456(96)00075-X \|u Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996; 17(4):343-346.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1016/S0165-4608(96)90076-X \|u Mitelman F. ISCN: An International System for Human Cytogenetic Nomenclature. 1995.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1016/S1470-2045(15)00193-X \|u Burnett AK, Russell NH, Hills RK. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015; 16(13):1295-1305.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1016/j.beha.2014.04.006 \|u Lo-Coco F, Hasan SK. Understanding the molecular pathogenesis of acute promyelocytic leukemia. Best Pract Res Clin Haematol. 2014; 27(1):3-9.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1016/j.blre.2017.09.001 \|u Jillella AP, Kota VK. The global problem of early deaths in acute promyelocytic leukemia: a strategy to decrease induction mortality in the most curable leukemia. Blood Rev. 2018; 32(2):89-95.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1016/j.leukres.2009.08.001 \|u Kiguchi T, Yoshino Y, Yuan B. Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia. Leuk Res. 2010; 34(3):403-405.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1016/j.leukres.2013.07.030 \|u Lou Y, Suo S, Tong H. Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy. Leuk Res. 2013; 37(11):1451-1456.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1038/leu.2014.240 \|u Rahmé R, Thomas X, Recher C. Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients. Leukemia. 2014; 28(12):2422-2424.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1038/leu.2016.122 \|u Cicconi L, Divona M, Ciardi C. PMLRARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy. Leukemia. 2016; 30(10):1987-1992.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1038/leu.2017.71 \|u Lehmann S, Deneberg S, Antunovic P. Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997-2013. Leukemia. 2017; 31(6):1457-1459.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1038/s41375-018-0139-4 \|u Kayser S, Schlenk RF, Platzbecker U. Management of patients with acute promyelocytic leukemia. Leukemia. 2018; 32(6):1277-1294.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1038/s41375-020-0758-4 \|u Kayser S, Rahmé R, Martínez-Cuadrón D. Outcome of older (70 years) APL patients frontline treated with or without arsenic trioxide- an International Collaborative Study. Leukemia. 2020; 34(9):2333-2341.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1038/sj.leu.2400756 \|u Kiyoi H, Naoe T, Yokota S. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia. 1997; 11(9):1447-1452.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1038/sj.leu.2400812 \|u Yokota S, Kiyoi H, Nakao M. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia. 1997; 11(10):1605-1609.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1038/sj.leu.2402723 \|u Noguera NI, Breccia M, Divona M. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia. 2002; 16(11):2185-2189.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1038/sj.leu.2403766 \|u Schlenk RF, Germing U, Hartmann F. High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia. 2005; 19(6):978-983.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1053/shem.2002.33610 \|u Davison K, Mann KK, Miller WH, Davison K. Arsenic trioxide: mechanisms of action. Semin Hematol. 2002; 39(2 Suppl 1):3-7.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1056/NEJMoa1300874 \|u Lo-Coco F, Avvisati G, Vignetti M. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013; 369(2):111-121.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1073/pnas.0813280106 \|u Hu J, Liu YF, Wu CF. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2009; 106(9):3342-3347.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1080/01621459.1958.10501452 \|u Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53(282):457-481.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1111/bjh.12931 \|u Paulson K, Serebrin A, Lambert P. Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study. Br J Haematol. 2014; 166(5):660-666.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1111/j.1365-2141.2000.02442.x \|u De Botton S, Chevret S, Sanz M. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol. 2000; 111(3):801-806.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1182/blood-2002-03-0886 \|u Pagano L, Pulsoni A. Second malignancy after treatment of acute promyelocytic leukemia: experience of GIMEMA trials. Blood. 2002; 100(4):1514-1515.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1182/blood-2007-07-100669 \|u de la Serna J, Montesinos P, Vellenga E. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with alltrans retinoic acid and idarubicin. Blood. 2008; 11(7):3395-4302.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1182/blood-2010-02-269621 \|u Powell BL, Moser B, Stock W. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010; 116(19):3751-3757.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1182/blood-2010-03-276196 \|u Lo-Coco F, Avvisati G, Vignetti M. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA- 2000 trial of the GIMEMA group. Blood. 2010; 116(17):3171-3179.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1182/blood-2011-04-346437 \|u Park JH, Qiao B, Panageas KS. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 2011; 118(5):1248-1254.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1182/blood-2016-02-699439 \|u Zhu H, Hu J, Chen L. The 12-year follow- up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia. Blood. 2016; 128(11):1525-1528.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1182/blood-2019-01-894980 \|u Sanz MA, Fenaux P, Tallman MS. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019; 133(15):1630-1643.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1182/blood.V99.12.4326 \|u Thiede C, Steudel C, Mohr B. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002; 99(12):4326-4335.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1200/JCO.2003.04.036 \|u Cheson BD, Bennett JM, Kopecky KJ. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003; 21(24):4642-4649.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1200/JCO.2010.29.2268 \|u Montesinos P, González JD, González J. Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic acid and anthracycline-based chemotherapy. J Clin Oncol. 2010; 28(24):3872-3879.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1200/JCO.2010.32.2107 \|u Ghavamzadeh A, Alimoghaddam K, Rostami S. Phase II study of singleagent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol. 2011; 29(20):2753-2757.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1200/JCO.2016.67.1982 \|u Platzbecker U, Avvisati G, Cicconi L. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol. 2016; 35(6):605-612.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.1214/aos/1176350951 \|u Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16(3):1141-1154.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.3109/10428194.2013.842985 \|u Poiré X, Moser BK, Gallagher RE. Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. Leuk Lymphoma. 2014; 55(7):1523-1532.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.3324/haematol.2009.013243 \|u Cervera J, Montesinos P, Hernández-Rivas JM. Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Haematologica. 2010; 95(3):424-431.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.3390/cancers11101591 \|u Noguera NI, Catalano G, Banella C. Acute promyelocytic leukemia: update on the mechanisms of leukemogenesis, resistance and on innovative treatment strategies. Cancers. 2019; 11(10):1591.
999	C	5	\|2 Crossref \|9 -- missing cx lookup -- \|a 10.7326/0003-4819-103-4-620 \|u Bennett JM, Catovsky D, Daniel MT. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985; 103(4):620-625.
999	C	5	\|2 Crossref \|u R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria. 2014.
999	C	5	\|2 Crossref \|u Swerdlow SH, Campo E, Harris NL. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th edition. 2017.

Library	Collection	CLSMajor	CLSMinor	Language	Author

Marc 21

h1

h2

h3

h4

h5

h6